Be the first to receive investor updates.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Fusce tortor nulla, efficitur at magna sed, gravida venenatis lectus. Sed viverra est ac lectus viverra, condimentum efficitur metus condimentum.
Company Highlights
A Mature IP Portfolio, Innovative R&D, and Solid Financial Backbone
Patent Filings
• 14 Patents families
• 30 patents filed or granted
• Patent filing program
• Novel psychedelic compounds
• Integration of delivery platforms
• Methods of use in psychiatric indications
• Drug discovery pipeline
Scientific
• 15 different drug research programs
• Targeting various indications such as Alcohol Use Disorder, depression, eating disorders and other binge behaviours
• Demonstrated safety POC of proprietary AUD molecule designed to be shorter acting, more scalable and accessible
• Pre-clinical studies progressing lead programs towards IND filings and Phase I/II clinical studies
• Partnership with leading universities & KOL's
Financial
• C$9.4 M raised to date.
• Strategic shareholders including top Israeli institutional funds
• CSE – Commenced trading in May 2021
• FSE – Commenced trading in August 2021
• Nasdaq – Commenced trading in November 2022
• No debt
Why We’re Different
We develop our proprietary treatments to be self-administered and show immediate results.
The information presented in this table is based solely on the Company’s own market research. Actual information may contradict the Company’s findings.
The Opportunity
The market of alcohol-related psychedelic treatments has low competitive density.
1.6%
of clinical trials are
alcohol-related
There are only 21 Alcohol related clinical trials,
... out of a total of 1302 registered clinical trials of psychedelics.
Investor Information
Learn more about Clearmind’s unique approach and strategy.
Governance
Access Clearmind's corporate information.
Board Diversity Matrix
ViewArticles of association
ViewCode of conduct and ethics
ViewAudit committee charter
ViewCompensation committee charter
ViewNominating and corporate governance committee charter
ViewInvestor Frequently Asked Questions
How can I invest in Clearmind?
You can purchase Clearmind shares through a registered broker-dealer of your choice. You cannot purchase securities directly from the Company. To buy shares, you can either go through an investment advisor or you can use an online brokerage account from any major financial institution in your country. Simply type in the relevant symbol mentioned below or type in "Clearmind Medicine" (the corporate name) to find the stock. For information about investing in stocks, you may want to consult a financial professional to explain to you the risks and suitability when investing.
Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol "CMND", the Frankfurt Stock Exchange under the symbol “CWY” and on the Nasdaq under the symbol "CMND".
What is Clearmind’s fiscal year?
Our fiscal year end is October 31.
How does Clearmind prepare their financial statements?
Clearmind prepares its interim financial statements in accordance with International Financial Reporting Standards (“IFRS”).
Does Clearmind pay any dividends?
To this date, Clearmind has not paid any dividends and the company does not anticipate paying any cash dividends in the foreseeable future.
When will the next financials be released?
For the latest financials please look at our SEDAR filings.
Join Us
Let's Make History
